AbbVie lowers Q2 and FY 2022 guidance on acquired R&D assetshttps://seekingalpha.com/news/3854809-abbvie-lowers-q2-and-fy-2022-guidance-on-acquired-research-development-assets-milestones-expense AbbVie (NYSE:ABBV) said Wednesday that its Q2 and fiscal year 2022 results will be negatively impacted by in-process research and development (IPR&D) costs due to acquired assets as well as milestones expense. For Q2 2022, AbbVie (ABBV) expects acquired IPR&D and milestones expense of $269 million on a pre-tax basis. In an SEC filing, the company said that for Q2, it projects EPS of $3.24-3.28, excluding non-recurring items, down from $3.38-$3.42. Consensus is $3.43. For FY 2022, it now expects EPS of $13.78-13.98, excluding non-recurring items, down from $13.92-$14.12. Consensus is $14.01. After its Q1 financial results in late April, AbbVie (ABBV) first lowered its full-year guidance. In March, AbbVie (ABBV) said it would acquire Syndesi Therapeutics for $130M upfront and up to $870M in milestone payments.